Adagene doses first patient in Phase 1 trial of muzastotug plus INCA33890 for MSS colorectal cancer
Adagene Inc. reported that the first patient has been dosed in a Phase 1 open‑label study of the combination of its anti‑CTLA‑4 antibody muzastotug with Incyte’s bispecific INCA33890 in microsatellite‑stable colorectal cancer. The trial targets third‑line patients, including those with liver metastases, and is sponsored by Incyte under a collaboration announced in April 2026. Muzastotug carries FDA Fast Track designation.
Why it matters
The dosing milestone moves the program into the safety‑assessment stage, which could influence Adagene’s valuation and future financing needs. The pre‑market price jump reported by rttnews.com shows immediate market enthusiasm for the trial progress.
Key facts
- 1The first patient was dosed in a Phase 1 clinical study of muzastotug plus INCA33890. investing.com
- 2The open‑label trial evaluates the combination in microsatellite‑stable colorectal cancer. investing.com
- 3The study targets third‑line MSS colorectal cancer patients, with or without liver metastases. investing.com
- 4Incyte is sponsoring and conducting the study under a collaboration first announced in April 2026. investing.com
- 5Muzastotug has received FDA Fast Track designation. investing.com
- 6ADAG shares rose 10.47% in pre‑market trading to $2.85. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.